RecruitingNot applicableNCT07364474

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Studying Uveal melanoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Eric Wehrenberg-Klee, MD
Massachusetts General Hospital
Intervention
Melphalan through Percutaneous Hepatic Perfusion(drug)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
2026 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07364474 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials